HOME >> MEDICINE >> NEWS
Research guides medication choices for young Asthma patients

New research should help physicians choose effective asthma medications tailored to the characteristics of their individual patients. Researchers at National Jewish Medical and Research Center and their colleagues in the National Heart, Lung and Blood Institute's (NHLBI) Childhood Asthma Research and Education Network identify in the February Journal of Allergy and Clinical Immunology specific characteristics in children associated with better responses to inhaled steroids and to leukotriene receptor antagonists. The research builds on a trend to use scientific evidence, rather than trial-and-error, to customize medication choices for specific individuals.

"We found that responses to these two medications varied considerably from child to child," said Stanley Szefler, M.D., lead author and Professor of Pediatrics at National Jewish Medical and Research Center. "Young asthma patients with low pulmonary function or evidence of allergic inflammation are most likely to respond well to inhaled corticosteroids and should try those first. Other young patients can try either the inhaled steroids or leukotriene receptor antagonists first. Patients under 10 years of age who have had asthma for a short time may respond well to the leukotriene receptor antagonists." Inhaled corticosteroids are broadly acting anti-inflammatory medications that are applied directly to the airways by breathing them in.

Leukotriene receptor antagonists, taken in pill form, act systemically to block substances call leukotrienes, which are associated with inflammation and allergic reactions. Both medications are considered effective, but inhaled steroids are currently the preferred long-term therapy for persistent asthma.

"If we can pinpoint in advance which children will do better with a certain type of therapy, we can improve their lives more quickly and save them the risk of trying medications that are less effective for them," noted James Kiley, Ph.D., director of the N
'"/>

Contact: William Allstetter
allstetterw@njc.org
303-398-1002
National Jewish Medical and Research Center
1-Feb-2005


Page: 1 2 3

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Research offers hope of new treatments for liver damage
3. Research suggests possible blood test for multiple sclerosis
4. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
5. 2005 Award for Basic Research in Biological Mineralization
6. 2005 Craniofacial Biology Research Award
7. 2005 Research in Dental Caries Award
8. 2005 Research in Prosthodontics and Implants Award
9. 2005 Basic Research in Periodontal Disease Award
10. 2005 Research in Oral Biology Award
11. 2005 Pulp Biology Research Award

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Research guides medication choices for young Asthma patients

(Date:5/19/2013)... Atlanta, GA (PRWEB) May 19, 2013 The ... and 2pm at the Columbus Georgia Convention & Trade Center ... are invited to attend. AMTC auditions are free of charge. ... the starting point for hundreds of successful artists and grads ... new face for European Tombolini , Chris Young - on ...
(Date:5/19/2013)... The Da Vinci robot lawyers at Wright & ... first trial involving a Da Vinci surgical robot lawsuit. ... was filed by the widow of a man who ... robot-assisted prostate removal, according to a report from Bloomberg ... alleges those complication’s hastened his death. (Estate of ...
(Date:5/18/2013)... The American Society for Gastrointestinal Endoscopy (ASGE) will honor ... ninth annual ASGE Crystal Awards on Sunday, May 19, ... year,s event will begin at ... Held in conjunction with Digestive Disease Week (DDW), the ... and scientific pursuit. The event will recognize the 2013 ...
(Date:5/18/2013)... Online watch retailer Time and Gems is offering ... at a fraction of its usual cost. With great deals ... buyers are urged to take advantage of Time and Gems’ ... from a brick-and-mortar store, buyers now have the option of ... unbelievable rates. Although some buyers may have qualms about buying ...
(Date:5/18/2013)... (HealthDay News) -- Just a few extra cups of ... an autoimmune liver disease known as primary sclerosing cholangitis ... Mayo Clinic in Rochester, Minn., found that drinking coffee ... disease, which can lead to cirrhosis of the liver, ... not prove a cause-and-effect relationship. "While rare, ...
Breaking Medicine News(10 mins):Health News:Actors, Models and Talent for Christ Hosting Auditions in Columbus, GA June 1st in Search of Local Talent 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 4Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 2Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 3Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 4Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 5Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 6Health News:ASGE and ASGE foundation hold Crystal Awards dinner as part of Digestive Disease Week®, May 19, in Orlando 7Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 2Health News:Time and Gems Offers Buyers the Largest Collection of Rolex Watches Yet 3Health News:Study Links Coffee to Lower Risk for Rare Liver Disease 2
(Date:5/17/2013)...  Sanofi (EURONEXT: SAN and NYSE: SNY ) ... , examining the selective JAK2 inhibitor SAR302503 for ... groups. The primary endpoint assessed the proportion of patients ... reported in previous trials, the most common adverse events ... be presented at an upcoming medical congress. ...
(Date:5/17/2013)...  Boston Scientific Corporation (NYSE: BSX ) ... Program May 21-24 in Paris . ... rich and diversified set of data this year at ... global chief medical officer, Boston Scientific.  "The primary endpoint ... NG PROMUS trial, which evaluated our Promus PREMIER ™ ...
(Date:5/16/2013)... , May 16, 2013  PTC Therapeutics, Inc., ... on Form S-1 with the U.S. Securities and Exchange ... of its common stock. The number of shares to ... have not been determined. (Logo:  http://photos.prnewswire.com/prnh/20010919/PTCLOGO ... are acting as joint book-running managers for the offering. ...
Breaking Medicine Technology:Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 2Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 3Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 4Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 5Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 6Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 7Boston Scientific Schedule of Major Events and Presentations at EuroPCR 2013 8PTC Therapeutics, Inc. Files Registration Statement for Proposed Initial Public Offering 2
Cached News: